Dr. Paul Watkins is a recently retired research scientist at the Kennedy Krieger Institute and Professor of Neurology at the Johns Hopkins University School of Medicine. Dr. Watkins did his undergraduate, graduate and medical training at Johns Hopkins, receiving a medical degree and doctoral degree in biochemistry. In the years which followed, he served as both a research associate and medical staff fellow at the National Institutes of Health, as well as commissioned officer service for the United States Public Health Service. Dr. Watkins has been a dear friend and supporter of the United Leukodystrophy Foundation since its inception. He has had a profound impact on the lives and careers of many trainees and early career scientists in the leukodystrophy field.” Dr. Paul Watkins is a recently retired research scientist at the Kennedy Krieger Institute and Professor of Neurology at the Johns Hopkins University School of Medicine. Dr. Watkins did his undergraduate, graduate and medical training at Johns Hopkins, receiving a medical degree and doctoral degree in biochemistry. In the years which followed, he served as both a research associate and medical staff fellow at the National Institutes of Health, as well as commissioned officer service for the United States Public Health Service. Dr. Watkins has been a dear friend and supporter of the United Leukodystrophy Foundation since its inception. He has had a profound impact on the lives and careers of many trainees and early career scientists in the leukodystrophy field.”
Dr. Paul Watkins is a recently retired research scientist at the Kennedy Krieger Institute and Professor of Neurology at the Johns Hopkins University School of Medicine. Dr. Watkins did his undergraduate, graduate and medical training at Johns Hopkins, receiving a medical degree and doctoral degree in biochemistry. In the years which followed, he served as both a research associate and medical staff fellow at the National Institutes of Health, as well as commissioned officer service for the United States Public Health Service. Dr. Watkins has been a dear friend and supporter of the United Leukodystrophy Foundation since its inception. He has had a profound impact on the lives and careers of many trainees and early career scientists in the leukodystrophy field.”
CALL FOR ABSTRACTS!
NOW ACCEPTING SUBMISSIONS fOR 2024 Poster Presentations that will take place the evening of the Scientific Symposium
The ULF’s mission includes nurturing the future leaders of the scientific and medical sector to ensure advances in research to achieve our community’s goals: newborn screening techniques, faster diagnosis, early intervention, improved treatment options, and most importantly, a cure! The ULF is honored to name it’s annual Poster Competition after Dr. Paul A. Watkins for his legacy of improving the lives of those affected by leukodystrophy through his unwavering dedication to the advancement of research.
The United Leukodystrophy Foundation (ULF) is interested in receiving abstracts that highlight new and innovative leukodystrophy research. The following focus areas include but are not limited to:
Invited Audiences
Academics, researchers, industry, government agencies, healthcare professionals, and other individuals who have been involved in rare disease research studies are invited to submit an abstract for approval to be included in the ULF Leukodystrophy Poster Hall.
Eligibility
- Professional (medical residents/fellows/professionals)
- Trainees (postdoctoral scholars, graduate students, or undergraduate students)
- The submitted research must have been conducted at an academic institution.
All abstracts must be noncommercial and without trade names or logo by any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by or used on patients.
Schedule of dates:
| Call for abstracts | February 15th, 2024 |
| Abstract submission deadline via submission form | June 1st, 2024 |
| Accepted Abstract Attendees Conference Registration date | June 7th , 2024 |
| ULF Poster Hall Set Up | June 27th, 2024 |
General Guidelines
- All abstracts must be submitted by June 1st, 2024. Abstracts will only be accepted via this portal.
- Posters should include data for consideration, Preliminary and pilot data will be accepted.
- Abstracts should be original in research, include empirical evidence, and not have been widely presented or circulated prior to the ULF conference.
- Authors who use resources that are not their own (pictures, charts, graphics, etc.) must cite the original source in their abstract.
- Referral to webpages or URLs may not be used in the abstract.
- Abstracts should be no more than 350 words and utilize the following specifications:
- Minimum font size: 11
- Single-spaced rows
- One-inch margins
- The following content is required:
- Title of Abstract
- Authors, institution, institution location (city, state or province and country)
Abstract Evaluation Process
Abstracts will be evaluated by the ULF Abstract Review Committee. The main contact for each abstract will be notified by ULF staff about acceptance or nonacceptance on June 2nd, 2024. If an abstract is accepted, the main contact will be provided with additional information about the poster presentation format requirements.
Three selected abstracts will be chosen by the review committee for Lightening Round oral presentations at the ULF Science Symposium.
Submission of an abstract constitutes a commitment by the presenting author to present their work in the Poster Hall if the abstract is accepted. All additional abstract authors are encouraged to purchase a registration to attend the ULF Conference.
Congratulations to the winners of the 2023 presentation!
